ImaginAb’s Post

Learn how 3D tissue models and high-content imaging are transforming drug toxicity research in this on-demand webinar! Join Dr. Oksana Sirenko (Molecular Devices) and Dr. Kristin Bircsak (MIMETAS) as they explore: ✔ Scaling high-throughput workflows with the OrganoPlate® platform and high-content imaging ✔ Building disease-related 3D model workflows for drug discovery ✔ Automating 3D drug screening for efficiency 🔗 https://lnkd.in/eAkmEz7B #ToxicityResearch #3DModels #DrugDiscovery #Automation #Webinar

Are you working on the development of novel #Molecular #RadioTherapy agents? This poster could be of interest for you! It describes the differents approaches at Oncodesign Services to support the development of radiopharmaceuticals: ▶️Lead optimization ▶️Bioconjugaison chemistry ▶️3D models ▶️In vivo models ▶️ PET-Imaging and SPECT-Imaging monitoring... Discover more information👇 https://lnkd.in/eAAMBmGY #Radiopharmaceutical #Theranostics #Innovation #Imaging #Radiotherapy #DrugDevelopment

Ophthopedia Update:Fluid Pathways in Age-Related Macular Degeneration Elucidated with Advanced Retinal Imaging: Subretinal (SRF) and intraretinal fluid (IRF) are tried and true biomarkers of neovascular activity in age-related macular degeneration (AMD) indicating the need for intravitreal anti-VEGF therapy. But it is becoming abundantly clear that the exudative pathways in AMD are much more complex. Although neovascular fluid is certainly a common complication of AMD, other mechanisms should be considered including degenerative and tractional etiologies.1 #Ophthalmology #Retina #Ophthotwitter

Why is imaging so important in preclinical research for renal vascular interventions? In this CT scan of arterial and venous renal vascularization in a pig, you’ll see that the renal vein can be bifid. Retrograde catheterization can therefore be very challenging if 100% of the renal blood must be diverted. #preclinical #CTscan #VascularResearch #RenalResearch #MedTech

This article examines hydroxyl dendrimers targeting reactive microglia in cerebral palsy, revealing differential uptake that aids in designing targeted nanomedicines for neuroinflammation. You can check it out here: https://lnkd.in/gT9Ktakn #nanotechnology #biotechnology #pharmaceuticals #science #Innovation #research #healthTech #medicalDevices #biomedical #clinicalTrials #drugDelivery #precisionMedicine #healthcareInnovation #inflammation

Reviewing the therapeutic applications of engineered exosomes: in this article, Verena Poinsot, Nathalie Pizzinat and Varravaddheay ONG-MEANG at Université de Toulouse emphasised the use of alternative exosome-mimics, including cell-membrane-coated artificial nanocarriers and hybrid structures combining exosomes with liposomes https://lnkd.in/ehreGk6z They discussed the strategies for loading drugs onto these carriers and provide an overview of current clinical trials involving exosomes or exosome-like structures, and outlined remaining questions before considering exosome-like systems for effective therapeutic delivery #exosomes #extracellularvesicles #drugdelivery #nanomedicine #Vesiculab

Preclinical glaucoma news from Market Scope: NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90), with offices in Canada and Israel, reported Dec. 6 findings of a preclinical study of its lead candidate, #ExoPTEN, for repairing optic nerve damage. Researchers utilized a rodent model of optic nerve crush to simulate the damage associated with conditions such as glaucoma. Treated eyes regained nearly normal retinal activity, as evidenced by electrical tests, NurExone said. #glaucoma #preclinical #neurodegeneration #nerveregeneration #neuroprotection

The Osteoarthritis Research Society International Congress 2024 will take place in Vienna, Austria, from April 18 to 21. Our Chief Medical Officer, Professor francis berenbaum, is scheduled to deliver an oral presentation on Friday, April 19, 2024. His presentation is titled IN-MOTION: "Pioneering a Phase 2b Clinical Trial Tailored for Inflamed Phenotypes in Knee Osteoarthritis with Intraarticular Liraglutide." Also, Coralie Meurot, our preclinical research scientist, will present her poster titled "Intra-articular Administration of Liraglutide Mitigates Synovial Tissue Alteration and Cartilage Degradation in Preclinical Osteoarthritis Models" during the poster presentation session. #4P004 #clinicaltrial #OARSI #Biotech.

MedChemAdvent 21. 𝐅𝐥𝐮𝐫𝐩𝐢𝐫𝐢𝐝𝐚𝐳 (18𝐅) (brand name Flyrcado) Flurpiridaz is a cyclotron-produced radioactive diagnostic agent for use with positron emission tomography (PET) myocardial perfusion imaging (MPI) to evaluate for myocardial ischemia and infarction. It is a first-of-its-kind imaging tracer for PET scans that helps assess the perfusion of heart muscle cells and gives a clearer picture of blocked arteries in the heart and any damage to cardiac tissue. Flurpiridaz was discovered by Lantheus (formerly known as Bristol-Myers Squibb Medical Imaging) and GE HealthCare did further development. The compound is a Mitochondrial Complex I (MC-I) inhibitor. It demonstrates rapid uptake by cardiomyocytes with high first-pass extraction fraction by the heart and slow washout due to high specificity for and potent binding to MC-1. During the discovery of various pyridazinone analogs, a structure-activity relationship (SAR) assessment indicated a preference for the fluorine label to be incorporated on an alkyl side chain rather than directly on the heterocyclic moiety. See the paper on Flurpiridaz discovery here: https://lnkd.in/e2JVeggu 𝘐𝘯 𝘵𝘩𝘦𝘴𝘦 𝘭𝘢𝘴𝘵 𝘥𝘢𝘺𝘴 𝘰𝘧 2024 𝘥𝘶𝘳𝘪𝘯𝘨 𝘈𝘥𝘷𝘦𝘯𝘵, 𝘸𝘦 𝘸𝘰𝘶𝘭𝘥 𝘭𝘪𝘬𝘦 𝘵𝘰 𝘳𝘦𝘤𝘢𝘭𝘭 𝘴𝘰𝘮𝘦 𝘥𝘳𝘶𝘨 𝘮𝘰𝘭𝘦𝘤𝘶𝘭𝘦𝘴 𝘵𝘩𝘢𝘵 𝘩𝘢𝘷𝘦 𝘣𝘦𝘦𝘯 𝘢𝘱𝘱𝘳𝘰𝘷𝘦𝘥 𝘣𝘺 𝘵𝘩𝘦 𝘍𝘋𝘈 𝘪𝘯 2024. 𝘌𝘢𝘤𝘩 𝘥𝘢𝘺 𝘶𝘯𝘵𝘪𝘭 𝘊𝘩𝘳𝘪𝘴𝘵𝘮𝘢𝘴 𝘸𝘦 𝘩𝘪𝘨𝘩𝘭𝘪𝘨𝘩𝘵 𝘰𝘯𝘦 𝘰𝘧 𝘵𝘩𝘦𝘮 𝘪𝘯 𝘰𝘶𝘳 𝘔𝘦𝘥𝘊𝘩𝘦𝘮𝘈𝘥𝘷𝘦𝘯𝘵. 𝘌𝘯𝘫𝘰𝘺! #MedChemAdvent #DrugDiscovery #MedicinalChemistry #FDA #Flurpiridaz #PET #Fluorine

READ OF THE DAY: Grow organoids or spheroids that mimic the function, structure, and architecture of in vivo cells (Written By Brandy Sargent) https://lnkd.in/e6D9skd9 #Cellculture #celltherapy #lifescience #research #genetherapy #pharma #biotech CelVivo